A systematic review of biomarkers for disease progression in Alzheimer's disease.

ABSTRACT:

Background

Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true slowing of the neurodegenerative process. A systematic review was undertaken to determine what biomarkers for disease progression in Alzheimer's disease exist and how well they perform.

Methods

MEDLINE and Embase (1950-2011) were searched using five search strategies. Abstracts were assessed to identify papers meriting review in full. Studies of participants with probable Alzheimer's disease diagnosed by formal criteria were included. We made no restriction on age, disease duration, or drug treatment. We only included studies with a longitudinal design, in which the putative biom

SUBMITTER: McGhee DJ 

PROVIDER: S-EPMC3928315 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature